DDInter1254 DDInter1055
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Nabumetone {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Nabumetone {u} (Compound) causes {v} (Side Effect) Dysphagia
Dysphagia {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Nabumetone {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Nabumetone {u} (Compound) causes {v} (Side Effect) Dysphagia
Dysphagia {u} (Side Effect) is caused by {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Nabumetone {u} (Compound) causes {v} (Side Effect) Bullous eruption
Bullous eruption {u} (Side Effect) is caused by {v} (Compound) Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Nabumetone {u} (Compound) resembles {v} (Compound) Naproxen
Naproxen {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Nabumetone {u} (Compound) resembles {v} (Compound) Melatonin
Melatonin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Nabumetone {u} (Compound) resembles {v} (Compound) Melatonin
Melatonin {u} (Compound) downregulates {v} (Gene) TRIB3
TRIB3 {u} (Gene) is downregulated by {v} (Compound) Levofloxacin
Nabumetone {u} (Compound) resembles {v} (Compound) Naproxen
Naproxen {u} (Compound) causes {v} (Side Effect) Dysphagia
Dysphagia {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Nabumetone {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is associated with {v} (Disease) chronic obstructive pulmonary disease
chronic obstructive pulmonary disease {u} (Disease) is palliated by {v} (Compound) Levofloxacin
Nabumetone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Levofloxacin (Compound)
Nabumetone (Compound) causes Dysphagia (Side Effect) and Dysphagia (Side Effect) is caused by Levofloxacin (Compound)
Nabumetone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Nabumetone (Compound) causes Dysphagia (Side Effect) and Dysphagia (Side Effect) is caused by Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Nabumetone (Compound) causes Bullous eruption (Side Effect) and Bullous eruption (Side Effect) is caused by Sparfloxacin (Compound) and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Nabumetone (Compound) resembles Naproxen (Compound) and Naproxen (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Levofloxacin (Compound)
Nabumetone (Compound) resembles Melatonin (Compound) and Melatonin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Levofloxacin (Compound)
Nabumetone (Compound) resembles Melatonin (Compound) and Melatonin (Compound) downregulates TRIB3 (Gene) and TRIB3 (Gene) is downregulated by Levofloxacin (Compound)
Nabumetone (Compound) resembles Naproxen (Compound) and Naproxen (Compound) causes Dysphagia (Side Effect) and Dysphagia (Side Effect) is caused by Levofloxacin (Compound)
Nabumetone (Compound) binds MPO (Gene) and MPO (Gene) is associated with chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) is palliated by Levofloxacin (Compound)